Funds and ETFs iCAD, Inc.

Equities

ICAD

US44934S2068

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 21:00:00 20/05/2024 BST 5-day change 1st Jan Change
1.64 USD -6.29% Intraday chart for iCAD, Inc. +5.13% -7.34%
iCAD, Inc. provides artificial intelligence-powered cancer detection. Its ProFound Breast Health Suite enables medical providers and professionals to accurately and reliably identify where cancer may be hiding. Its Cancer Detection segment solutions include advanced artificial intelligence and image analysis workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing the prevalent cancers earlier, a range of upgradeable computer-aided detection systems and workflow solutions for digital breast tomosynthesis, full-field digital mammography, magnetic resonance imaging and computed tomography. ProFound Suite offers 360-degree solutions for cancer detection, density assessment, and personalized risk evaluation, all based on a 2D or 3D mammogram’s collection of images. ProFound Density Assessment standardizes and simplifies breast density reporting, algorithmically examining a woman’s breast anatomy from the mammogram image.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.64 USD
Average target price
4.833 USD
Spread / Average Target
+194.72%
Consensus
  1. Stock Market
  2. Equities
  3. ICAD Stock
  4. Funds and ETFs iCAD, Inc.